Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01364428 · ClinicalTrials.gov registry record · Phase 3
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 373
- Enrollment target
- 20
- Study locations
NCT01364428: Completed Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
NCT01364428 is a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 373 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01364428, a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 373 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy and safety of two different formulations of insulin degludec (IDeg) in subjects with type 2 diabetes.
Primary Outcome
Change from baseline in HbA1c after 22 weeks of treatment
Conditions Studied
Interventions
- DRUG insulin degludec
Study Locations (20)
Florida
- Novo Nordisk Investigational Site - Bradenton
- Novo Nordisk Investigational Site - Clearwater
- Novo Nordisk Investigational Site - Kissimmee
- Novo Nordisk Investigational Site - Miami
- Novo Nordisk Investigational Site - Tampa
- Novo Nordisk Investigational Site - West Palm Beach
California
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Greenbrae
- Novo Nordisk Investigational Site - Montclair
- Novo Nordisk Investigational Site - National City
- Novo Nordisk Investigational Site - Palm Springs
Arizona
- Novo Nordisk Investigational Site - Goodyear
- Novo Nordisk Investigational Site - Mesa
- Novo Nordisk Investigational Site - Phoenix
Louisiana
- Novo Nordisk Investigational Site - Metairie
- Novo Nordisk Investigational Site - Slidell
Alabama
- Novo Nordisk Investigational Site - Huntsville
Georgia
- Novo Nordisk Investigational Site - Atlanta
Illinois
- Novo Nordisk Investigational Site - Springfield
Indiana
- Novo Nordisk Investigational Site - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
What the finished NCT01364428 record still lists
NCT01364428 is an interventional study that assigns participants to a tested intervention. The registered 373 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which insulin degludec is the first listed.
NCT01364428 names 20 study sites across 8 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT01364428 about?
NCT01364428 is a clinical study titled "Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus". This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy and safety of two different formulations of insulin degludec (IDeg) in subjects with type 2 diabetes.
What is the current status of trial NCT01364428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 373 participants. The study started on 2011-06. Estimated completion is 2012-01.
What conditions does trial NCT01364428 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes.
What interventions are being tested in trial NCT01364428?
The interventions under investigation include: insulin degludec (DRUG).
Who is sponsoring clinical trial NCT01364428?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01364428 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01364428's enrollment target sits among peer trials
373 97th of 348 higher than 251 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07276750 · 373 participants · NA
Coaching and Leadership in Autism Support Settings
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia